top of page
Executive Spotlights

Gilead to buy CymaBay in $4.3B deal for liver disease drug

Foster City, CA,  February 12, 2024 (Yahoo Finance) -- Gilead Sciences announces acquisition of CymaBay Therapeutics in a $4.3 billion deal.  The proposed acquisition will grant Gilead access to an experimental treatment CymaBay's liver disease drug for primary biliary cholangitis.

Read full article here.

Recent Posts

See All


Life Science Headlines
bottom of page